Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS OR NOT YET ON DIALYSIS

Trial Profile

AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS OR NOT YET ON DIALYSIS

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 04 Jul 2018 Planned End Date changed from 29 Oct 2021 to 30 Oct 2021.
    • 04 Jul 2018 Planned primary completion date changed from 29 Oct 2021 to 30 Oct 2021.
    • 25 Jun 2018 Planned End Date changed from 28 Oct 2021 to 29 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top